Non-coding RNAs (ncRNA) are widely expressed in the central nervous system of mammalian, with tissue and cell-type specificity. Many studies have shown that ncRNAs play a complex and dynamic regulation role of various signaling pathways in neurodegenerative diseases, including but not limited to Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. It is known that some antisense transcripts, such as microRNA, LncRNA and circRNA, can directly induce or promote the occurrence and progression of diseases. In different neurodegenerative diseases, ncRNAs could show common or unique functions in the pathogenesis, so as to ncRNA/mRNA network. Further understanding of the biogenesis and function of ncRNA will lead to the development of novel diagnostic biomarkers and effective treatments in the clinic.
Neurodegenerative diseases are commonly associated with neuroimmune disorders, abnormal protein aggregation, oxidative stress or other pathological changes in the brain, accompanied by neuron loss and brain dysfunction. In the early stage of neurodegenerative diseases, the pathological changes lead to abnormal expression of ncRNA, which may participate in the occurrence and development of diseases by regulating the expression of related mRNA. Some ncRNAs, like miRNA, are hard to be degraded and can be released or spread to cerebrospinal fluid, blood and other circulatory systems by exosomes, which provide the possibility for early detection of diseases. Some ncRNAs, such as cirRNA, have sponge-like adsorption of miRNA, which may play a therapeutic role by regulating miRNA expression. In addition to lncRNA, miRNA and cirRNA, there are more potential functions and applications of ncRNA to be identified, explored and applied to clinical diagnosis and treatment for neurodegenerative diseases.
Our Research Topic aims to discuss the ncRNA network involved in neurodegenerative diseases and evaluate the potential clinic applications of ncRNA on disease prevention and treatment.
- To profile ncRNA expression in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and so on.
- To investigate the network and function of ncRNAs, including microRNA, LncRNA, circRNA, etc in neurodegenerative diseases.
- To reveal the molecular mechanism of ncRNA mediated neuronal loss and glial dysfunction involving neuroimmune disorder, abnormal protein aggregation, oxidative stress and others that contribute to neurodegenerative diseases.
- To evaluate ncRNAs as a biomarker in Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis or other neurodegenerative diseases for early diagnosis, differential diagnosis and treatment evaluation in the clinic.
- To explore the potential therapy of ncRNAs in relieving, preventing and improving diseases.
Non-coding RNAs (ncRNA) are widely expressed in the central nervous system of mammalian, with tissue and cell-type specificity. Many studies have shown that ncRNAs play a complex and dynamic regulation role of various signaling pathways in neurodegenerative diseases, including but not limited to Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. It is known that some antisense transcripts, such as microRNA, LncRNA and circRNA, can directly induce or promote the occurrence and progression of diseases. In different neurodegenerative diseases, ncRNAs could show common or unique functions in the pathogenesis, so as to ncRNA/mRNA network. Further understanding of the biogenesis and function of ncRNA will lead to the development of novel diagnostic biomarkers and effective treatments in the clinic.
Neurodegenerative diseases are commonly associated with neuroimmune disorders, abnormal protein aggregation, oxidative stress or other pathological changes in the brain, accompanied by neuron loss and brain dysfunction. In the early stage of neurodegenerative diseases, the pathological changes lead to abnormal expression of ncRNA, which may participate in the occurrence and development of diseases by regulating the expression of related mRNA. Some ncRNAs, like miRNA, are hard to be degraded and can be released or spread to cerebrospinal fluid, blood and other circulatory systems by exosomes, which provide the possibility for early detection of diseases. Some ncRNAs, such as cirRNA, have sponge-like adsorption of miRNA, which may play a therapeutic role by regulating miRNA expression. In addition to lncRNA, miRNA and cirRNA, there are more potential functions and applications of ncRNA to be identified, explored and applied to clinical diagnosis and treatment for neurodegenerative diseases.
Our Research Topic aims to discuss the ncRNA network involved in neurodegenerative diseases and evaluate the potential clinic applications of ncRNA on disease prevention and treatment.
- To profile ncRNA expression in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and so on.
- To investigate the network and function of ncRNAs, including microRNA, LncRNA, circRNA, etc in neurodegenerative diseases.
- To reveal the molecular mechanism of ncRNA mediated neuronal loss and glial dysfunction involving neuroimmune disorder, abnormal protein aggregation, oxidative stress and others that contribute to neurodegenerative diseases.
- To evaluate ncRNAs as a biomarker in Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis or other neurodegenerative diseases for early diagnosis, differential diagnosis and treatment evaluation in the clinic.
- To explore the potential therapy of ncRNAs in relieving, preventing and improving diseases.
